Association of DNA methylation, polymorphism and mRNA level of ALAS1 with antituberculosis drug-induced liver injury

Zhuolu Hao,Bing Han,Xinyue Zhou,Hongkai Jian,Xiaomin He,Lihuan Lu,Meiling Zhang,Hongqiu Pan,Honggang Yi,Shaowen Tang
DOI: https://doi.org/10.1080/14622416.2024.2392480
Pharmacogenomics
Abstract:Aim: To investigate the association of DNA methylation, genetic polymorphisms and mRNA level of aminolevulinate synthase 1 (ALAS1) with antituberculosis drug-induced liver injury (AT-DILI) risk.Methods: Based on a 1:1 matched case-control study with 182 cases and 182 controls, one CpG island and three single nucleotide polymorphisms (SNPs) were detected. ALAS1 mRNA level was detected in 34 samples.Results: Patients with methylation status were at high risk of AT-DILI (odds ratio: 1.567, 95% CI: 1.015-2.421, p = 0.043) and SNP rs352169 was associated with AT-DILI risk (GA vs. GG, odds ratio: 1.770, 95% CI: 1.101-2.847, p = 0.019). ALAS1 mRNA level in the cases was significantly lower than that in the controls (0.75 ± 0.34 vs. 1.00 ± 0.42, p = 0.021).Conclusion: The methylation status and SNP rs352169 of ALAS1 were associated with AT-DILI risk.
What problem does this paper attempt to address?